Cardio Diagnostics vs Senti Biosciences
CDIO and SNTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CDIO and SNTI compare
Cardio Diagnostics is the larger company, worth 1.3 times as much as Senti Biosciences ($5.6M against $4.4M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CDIO | SNTI |
|---|---|---|
| Size and price | ||
| Market cap | $5.6M | $4.4M |
| Share price | $1.89 | $0.140 |
| Change, 1 year | −49.5% | −92.6% |
| Change, 5 years | – | −99.9% |
| Beta (5Y) | 2.64 | 1.84 |
| Employees | 7 | – |
| StockData Score | ||
| Total score | 4 | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 368× | – |
| P/B | 1.0× | – |
| FCF yield | −103% | – |
| Profitability | ||
| Operating margin | −42650% | – |
| Net margin | −42722% | – |
| FCF margin | −38091% | – |
| Return on equity | −93.5% (better) | −466% |
| Return on invested capital | −136% | – |
| Financial health | ||
| Interest coverage | −564.9× | – |
| Current ratio | 17.44 (better) | 0.83 |
| Altman Z-score | −1.42 (better) | −21.36 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 24.3% | 18.6% |
| Held by insiders | 2.7% | – |
Go deeper
- CDIO stock overview
- CDIO income statement
- CDIO valuation and score
- SNTI stock overview
- SNTI income statement
- SNTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.